1.EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control) (2016) The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2015. EFSA Journal 14, 231.
2.Kaakoush, NO et al. (2015) Global epidemiology of Campylobacter infection. Clinical Microbiology Reviews 28, 687–720.
3.Mangen, M-JJ et al. (2016) The burden of Campylobacter-associated disease in six European countries. Microbial Risk Analysis 2, 48–52.
4.European Food Safety Authority (2011) Scientific opinion on Campylobacter in broiler meat production: control options and performance objectives and/or targets at different stages of the food chain. EFSA Journal 9, 141.
5.Mangen, M-JJ et al. (2007) Cost-utility analysis to control Campylobacter on chicken meat: dealing with data limitations. Risk Analysis 27, 815–830.
6.European Commission. Commission Regulation (EU) 2017/1495 of 23 August 2017 amending Regulation (EC) No 2073/2005 as regards Campylobacter in broiler carcases. (Accessed 4 September 2017).
7.Havelaar, A et al. (2000) Health burden in the Netherlands due to infection with thermophilic Campylobacter spp. Epidemiology and Infection 125, 505–522.
8.Mangen, M-JJ et al. (2005) The costs of human Campylobacter infections and sequelae in the Netherlands: A DALY and cost-of-illness approach. Food Economics-Acta Agriculturae Scandinavica, Section C 2, 35–51.
9.Kemmeren, JM et al. (2006) Priority Setting of Foodborne Pathogens: Disease Burden and Costs of Selected Enteric Pathogens. Bilthoven, The Netherlands: National Institute for Public Health and the Environment (RIVM) RIVM report 330080001/2006. Available at http://www.rivm.nl/bibliotheek/rapporten/330080001.pdf. (Accessed 26 February 2018).
10.Haagsma, JA et al. (2010) Disease burden of post-infectious irritable bowel syndrome in The Netherlands. Epidemiology and Infection 138, 1650–1656.
11.Mangen, M-JJ et al. (2013) The pathogen-and incidence-based DALY approach: an appropriated methodology for estimating the burden of infectious diseases. PLoS ONE 8, e79740.
13.European Food Safety Authority (2010) Scientific opinion on quantification of the risk posed by broiler meat to human campylobacteriosis in the EU. EFSA Journal 8, 1437.
14.Nauta, MJ et al. (2016) The effect of reducing numbers of Campylobacter in broiler intestines on human health risk. Microbial Risk Analysis 2, 68–77.
15.Nauta, MJ et al. (2009) A comparison of risk assessments on Campylobacter in broiler meat. International Journal of Food Microbiology 129, 107–123.
16.Chapman, B et al. (2016) A review of quantitative microbial risk assessment and consumer process models for Campylobacter in broiler chickens. Microbial Risk Analysis 2, 3–15.
17.Mangen, MJJ, de Wit, GA and Havelaar, AH (2007) Economic analysis of Campylobacter control in the Dutch broiler meat chain. Agribusiness 23, 173–192.
18.Havelaar, AH et al. (2007) Effectiveness and efficiency of controlling Campylobacter on broiler chicken meat. Risk Analysis 27, 831–844.
19.Katsma, WE et al. (2007) Assessing interventions to reduce the risk of Campylobacter prevalence in broilers. Risk Analysis 27, 863–876.
22.Scharff, RL (2012) Economic burden from health losses due to foodborne illness in the United States. Journal of Food Protection 75, 123–131.
23.Hoffmann, S, Batz, MB and Morris, JG Jr. (2012) Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens. Journal of Food Protection 75, 1292–1302.
24.Batz, M, Hoffmann, S and Morris, JG Jr. (2014) Disease-outcome trees, EQ-5D scores, and estimated annual losses of quality-adjusted life years (QALYs) for 14 foodborne pathogens in the United States. Foodborne Pathogens and Disease 11, 395–402.
25.Gold, MR, Stevenson, D and Fryback, DG (2002) HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annual Review of Public Health 23, 115–134.
26.Pitter, JG et al. (2015) Next steps to evidence-based food safety risk analysis: opportunities for health technology assessment methodology implementation. Studies in Agricultural Economics 117, 155–161.
27.Gibbens, JC et al. (2001) A trial of biosecurity as a means to control Campylobacter infection of broiler chickens. Preventive Veterinary Medicine 48, 85–99.
28.Habib, I et al. (2012) Campylobacter contamination in broiler carcasses and correlation with slaughterhouses operational hygiene inspection. Food Microbiology 29, 105–112.
29.de Zoete, MR, van Putten, JP and Wagenaar, JA (2007) Vaccination of chickens against Campylobacter. Vaccine 25, 5548–5557.
30.Greiner, W et al. (2003) A single European currency for EQ-5D health states. The European Journal of Health Economics, Formerly: HEPAC 4, 222–231.
31.Torgerson, DJ and Raftery, J (1999) Economic notes. Discounting. BMJ (Clinical Research) 319, 914–915.
32.Smith, DH and Gravelle, H (2001) The practice of discounting in economic evaluations of healthcare interventions. International Journal of Technology Assessment in Health Care 17, 236–243.
33.Cohen, BJ (2003) Discounting in cost-utility analysis of healthcare interventions: reassessing current practice. PharmacoEconomics 21, 75–87.
34.Bos, JM, Postma, MJ and Annemans, L (2005) Discounting health effects in pharmacoeconomic evaluations: current controversies. PharmacoEconomics 23, 639–649.
35.Hurst, N et al. (1997) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology 36, 551–559.
36.Gellynck, X et al. (2008) Economics of reducing Campylobacter at different levels within the Belgian poultry meat chain. Journal of Food Protection 71, 479–485.
40.World Health Organization. (2001) Macroeconomics and Health: Investing in Health for Economic Development. Geneva, Switzerland. ISBN 92 4 154550 X.
41.Shin, H et al. (2010) Socioeconomic costs of food-borne disease using the cost-of-illness model: applying the QALY method. Journal of Preventive Medicine and Public Health=Yebang Uihakhoe Chi 43, 352–361.
42.Zinsstag, J et al. (2011) From ‘one medicine’ to ‘one health’ and systemic approaches to health and well-being. Preventive Veterinary Medicine 101, 148–156.
43.Drummond, MF (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press, ISBN: 9780198529453.
44.Rothermich, EA and Pathak, DS (1999) Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. Clinical Therapeutics 21, 255–267.
45.Sommer, HM, Nauta, MJ and Rosenquist, H (2016) Translation of risk factor estimates into on-farm interventions and their effect on Campylobacter broiler flock prevalence. Microbial Risk Analysis 2, 27–37.
46.Sommer, HM et al. (2016) Analysis of farm specific risk factors for Campylobacter colonization of broilers in six European countries. Microbial Risk Analysis 2, 16–26.
47.van Wagenberg, CPA and van Horne, PLM (2016) Impact of technical and economic performance on costs of Campylobacter spp. interventions on broiler farms in six European countries. Microbial Risk Analysis 2, 38–47.
48.Garrison, LP et al. (2013) Performance-based risk-sharing arrangements – good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value in Health 16, 703–719.
49.Carlson, JJ et al. (2014) Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Applied Health Economics and Health Policy 12, 231–238.
50.Klemp, M, Fronsdal, KB and Facey, K (2011) What principles should govern the use of managed entry agreements? International Journal of Technology Assessment in Health Care 27, 77–83.